Efficacy of Metformin in Treating Complications Associated with Polycystic Ovary Syndrome (PCOS)
Abstract
Polycystic ovarian syndrome (PCOS) is an endocrine disorder that affects women of reproductive age and is characterized by hyperandrogenism, unpredictable ovulation, and a polycystic ovary shape. It is accompanied by metabolic problems, such as obesity and insulin resistance (IR). Factors contributing to PCOS include genetics, epigenetic changes, environmental factors, oxidative stress, chronic inflammation, mitochondrial dysfunction, and metabolic abnormalities. Insulin resistance is the most prevalent classical phenotype, and metformin was the first insulin-sensitizing drug to be used to study its role. Metformin, derived from galegine, inhibits mitochondrial function, activates AMPK, enhances hepatic insulin sensitivity, and lowers the risk of type 2 diabetes in PCOS patients. It also affects tumor growth, with a 30% reduction in the overall tumor onsets in T2DM patients. Metformin treatment has been linked to low rates of multiple pregnancies, increased fetal concentrations of sex hormone-binding globulin, and decreased levels of inflammatory cytokines. It can reduce the risk of endometrial cancer, type 2 diabetes mellitus, cardiovascular disease, dyslipidemia, and hypertension in women with PCOS.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.